3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
19
Ovarian Neoplasms
7
Leiomyosarcoma
6
Liposarcoma
4
Liposarcoma, Myxoid
3
Sarcoma, Ewing
2
Osteosarcoma
2
Solitary Fibrous Tumors
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Epithelial Cancer Recurrent
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma Uterus
1
Ichthyosis, X-Linked
1
Histiocytoma, Malignant Fibrous
1
Hemangioendothelioma
1
Fanconi Anemia, Complementation Group D1
1
Chondrosarcoma
1
Carcinosarcoma
1
Cancers With DNA Repair-Deficiency
1
Bone Neoplasms
1
Interventions
Gemcitabine
7
Doxorubicin
4
Cyclophosphamide
4
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Docetaxel
3
Cisplatin
3
regorafenib
2
Vincristine
2
Tranexamic Acid
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
Radiation
2
Proton Therapy
2
Nivolumab
2
Methotrexate
2
Methods
2
Interviews as Topic
2
Indocyanine Green
2
Everolimus
2
Curettage
2
Ascorbic Acid
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tocilizumab
1
samarium Sm-153 lexidronam
1
poly ICLC
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Bone Neoplasms
×
Trabectedin
×
Clear all
NCT05131386
2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
85 enrolled